Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom.
Department of Medicine, Institute of Neuroscience, University of Barcelona, Spain.
Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jun;6(6):636-645. doi: 10.1016/j.bpsc.2020.10.007. Epub 2020 Oct 27.
Cannabidiol (CBD) and Δ-tetrahydrocannabinol (THC) have been the most investigated cannabinoids at the human and preclinical levels, although the neurobiological mechanisms underlying their effects remain unclear. Human experimental evidence complemented by observational studies suggests that THC may have psychotogenic effects while CBD may have antipsychotic effects. However, whether their effects on brain function are consistent with their opposing behavioral effects remains unclear. To address this, here we synthesize neuroimaging evidence investigating the acute effects of THC and CBD on human brain function using a range of neuroimaging techniques, with an aim to identify the key brain substrates where THC and CBD have opposing effects. After a systematic search, a review of the available studies indicated marked heterogeneity. However, an overall pattern of opposite effect profiles of the two cannabinoids was evident with some degree of consistency, primarily attributed to the head-to-head challenge studies of THC and CBD. While head-to-head comparisons are relatively few, collectively the evidence suggests that opposite effects of THC and CBD may be present in the striatum, parahippocampus, anterior cingulate/medial prefrontal cortex, and amygdala, with opposite effects less consistently identified in other regions. Broadly, THC seems to increase brain activation and blood flow, whereas CBD seems to decrease brain activation and blood flow. Given the sparse evidence, there is a particular need to understand the mechanisms underlying their opposite behavioral effects because it may not only offer insights into the underlying pathophysiological mechanisms of psychotic disorders but also suggest potentially novel targets and biomarkers for drug discovery.
大麻二酚 (CBD) 和 Δ-四氢大麻酚 (THC) 是在人类和临床前水平上研究最多的大麻素,尽管它们的作用的神经生物学机制仍不清楚。人类实验证据和观察性研究表明,THC 可能具有致幻作用,而 CBD 可能具有抗精神病作用。然而,它们对大脑功能的影响是否与其相反的行为效应一致尚不清楚。为了解决这个问题,我们在这里综合了使用一系列神经影像学技术研究 THC 和 CBD 对人类大脑功能的急性影响的神经影像学证据,旨在确定 THC 和 CBD 具有相反作用的关键大脑底物。经过系统搜索,对现有研究的综述表明存在明显的异质性。然而,两种大麻素的作用模式总体上存在相反的趋势,具有一定程度的一致性,主要归因于 THC 和 CBD 的头对头挑战研究。虽然头对头比较相对较少,但总的来说,证据表明 THC 和 CBD 的相反作用可能存在于纹状体、海马旁回、前扣带回/内侧前额叶皮层和杏仁核,而在其他区域则不太一致地发现相反作用。总体而言,THC 似乎会增加大脑激活和血流量,而 CBD 似乎会减少大脑激活和血流量。鉴于证据稀少,特别需要了解它们相反的行为效应的机制,因为这不仅可以深入了解精神病障碍的潜在病理生理机制,还可以为药物发现提供潜在的新靶点和生物标志物。